Alva A et al. Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. ESMO 2020;Abstract LBA23.
Apolo AB et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: An open-label, single-centre, phase 2 trial. Lancet Oncol 2020;21(8):1099-109. Abstract
Bajorin DF et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle- invasive urothelial carcinoma (MIUC). ASCO Genitourinary Cancers Symposium 2021;Abstract 391.
Balar AV et al. Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin: Extended follow-up of KEYNOTE-057 Cohort A. ASCO Genitourinary Cancers Symposium 2021;Abstract 451.
Choueiri T et al. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. ESMO 2020;Abstract 696O_PR.
Choueiri TK et al. Updated efficacy results from the JAVELIN Renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020;31(8):1030-9. Abstract
Esagian SM et al. Long-term survival outcomes of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: A systematic review and individual patient data meta-analysis. ASCO Genitourinary Cancers Symposium 2021;Abstract 317.
Kikuchi E, Hayakawa N. Cabozantinib as a choice for platinum-refractory metastatic urothelial cancer. Lancet Oncol 2020;21(8):1005-6. Abstract
Kim HL et al. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? No, cytoreductive nephrectomy should no longer be routinely performed. Curr Opin Urol 2020;30(5):743-5. Abstract
Lee C-H et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). ASCO 2020;Abstract 5008.
Meza L et al. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered. Curr Opin Urol 2020;30(5):740-2. Abstract
Motzer RJ et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer 2020;8(2):e000891. Abstract
Pal S et al. Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study. ESMO 2020;Abstract 702O.
Plimack E et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. ASCO 2020;Abstract 5001.
Powles T et al. Clinical outcomes in post-operative ctDNApositive muscle-invasive urothelial carcinoma patients after atezolizumab adjuvant therapy. ESMO Immuno-Oncology Virtual Congress 2020;Abstract 1O.
Rosenberg JE et al. Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. ASCO Genitourinary Cancers Symposium 2020;Abstract 441.
Siefker-Radtke AO et al. ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001. ASCO 2020;Abstract 5015.
Vano Y et al. Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. ESMO 2020;Abstract LBA25.